{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:14:36Z","timestamp":1792095276670,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In end-stage renal disease (ESRD) patients receiving dialysis, anemia is common and related to a higher mortality rate. Erythropoietin (EPO) resistance and iron refractory anemia require red blood cell transfusions. Myelodysplastic syndrome (MDS) is a disease with hematopoietic dysplasia. There are limited reports regarding ESRD patients with MDS. We aim to assess whether, for ESRD patients, undergoing dialysis is a predictive factor of MDS by analyzing data from the Taiwan National Health Insurance Research Database. We enrolled 74,712 patients with chronic renal failure (ESRD) who underwent dialysis and matched 74,712 control patients. In our study, we noticed that compared with the non-ESRD controls, in ESRD patients, undergoing dialysis (subdistribution hazard ratio [sHR]\u2009=\u20091.60, 1.16\u20132.19) and age (sHR\u2009=\u20091.03, 1.02\u20131.04) had positive predictive value for MDS occurrence. Moreover, more units of red blood cell transfusion (higher than 4 units per month) was also associated with a higher incidence of MDS. The MDS cumulative incidence increased with the duration of dialysis in ESRD patients. These effects may be related to exposure to certain cytokines, including interleukin-1, tumor necrosis factor-\u03b1, and tumor growth factor-\u03b2. In conclusion, we report the novel finding that ESRD patients undergoing dialysis have an increased risk of MDS.<\/jats:p>","DOI":"10.1038\/s41598-020-72568-5","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T10:03:36Z","timestamp":1600855416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Min-Yu","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"72568_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt, J. L. & Lin, H. Y. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 23, 1631\u20131634 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"72568_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bmj.2.5546.213","volume":"2","author":"AB Shaw","year":"1967","unstructured":"Shaw, A. B. Haemolysis in chronic renal failure. Br. Med. J. 2, 213\u2013215 (1967).","journal-title":"Br. Med. J."},{"key":"72568_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0002-9343(68)90254-4","volume":"44","author":"JW Adamson","year":"1968","unstructured":"Adamson, J. W., Eschbach, J. W. & Finch, C. A. The kidney and erythropoiesis. Am. J. Med. 44, 725\u2013733 (1968).","journal-title":"Am. J. Med."},{"key":"72568_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/ki.1984.36","volume":"25","author":"RJS McGonigle","year":"1984","unstructured":"McGonigle, R. J. S., Wallin, J. D., Shadduck, R. K. & Fisher, J. W. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 25, 437\u2013444 (1984).","journal-title":"Kidney Int."},{"key":"72568_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/003693307502000616","volume":"20","author":"TF McDermott","year":"1975","unstructured":"McDermott, T. F., Galbraith, A. J. & Corlett, R. J. Inhibition of cell proliferation in renal failure and its significance to the uraemic syndrome: a review. Scott. Med. J. 20, 317\u2013327 (1975).","journal-title":"Scott. Med. J."},{"key":"72568_CR6","first-page":"170","volume":"97","author":"SF Wallner","year":"1981","unstructured":"Wallner, S. F. & Vautrin, R. M. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J. Lab. Clin. Med. 97, 170\u2013178 (1981).","journal-title":"J. Lab. Clin. Med."},{"key":"72568_CR7","first-page":"55","volume":"7","author":"ID Strickland","year":"1977","unstructured":"Strickland, I. D. et al. The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clin. Nephrol. 7, 55\u201357 (1977).","journal-title":"Clin. Nephrol."},{"key":"72568_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJM196703092761005","volume":"276","author":"CL Hampers","year":"1967","unstructured":"Hampers, C. L., Streiff, R., Nathan, D. G., Snyder, D. & Merrill, J. P. Megaloblatsic hematopoiesis in uremia and in patients on long-term hemodialysis. N. Eng. J. Med. 276, 551\u2013554 (1967).","journal-title":"N. Eng. J. Med."},{"key":"72568_CR9","first-page":"226","volume":"17","author":"AIK Short","year":"1980","unstructured":"Short, A. I. K., Winney, R. J. & Robson, J. S. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminum intoxication. Proc. Eur. Dial Transplant Assoc. 17, 226\u2013233 (1980).","journal-title":"Proc. Eur. Dial Transplant Assoc."},{"key":"72568_CR10","first-page":"295","volume":"19","author":"M Touam","year":"1983","unstructured":"Touam, M. et al. Aluminum0induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin. Nephol. 19, 295\u2013298 (1983).","journal-title":"Clin. Nephol."},{"key":"72568_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1001\/archinte.1979.03630450035012","volume":"139","author":"GL Barbour","year":"1979","unstructured":"Barbour, G. L. Effect of parathyroidectomy on anemia in chronic renal failure. Arch. Intern. Med. 139, 889\u2013891 (1979).","journal-title":"Arch. Intern. Med."},{"key":"72568_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nrc2047","volume":"7","author":"SJ Corey","year":"2007","unstructured":"Corey, S. J. et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer. 7, 118\u2013129 (2007).","journal-title":"Nat. Rev. Cancer."},{"key":"72568_CR13","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1182\/blood-2007-08-078139","volume":"111","author":"SD Nimer","year":"2008","unstructured":"Nimer, S. D. Myelodysplastic syndromes. Blood 111, 4841\u20134851 (2008).","journal-title":"Blood"},{"key":"72568_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","volume":"111","author":"S Park","year":"2008","unstructured":"Park, S. et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111, 574\u2013582 (2008).","journal-title":"Blood"},{"key":"72568_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.05.002","author":"A Hamza","year":"2019","unstructured":"Hamza, A. et al. Myelodysplastic syndrome in hemodialysis patients. Kidney Int. Rep. https:\/\/doi.org\/10.1016\/j.ekir.2019.05.002 (2019).","journal-title":"Kidney Int. Rep."},{"key":"72568_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","volume":"15","author":"E Lowrie","year":"1990","unstructured":"Lowrie, E. & Lew, N. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 15, 458\u2013482 (1990).","journal-title":"Am. J. Kidney Dis."},{"key":"72568_CR17","first-page":"276","volume":"12","author":"E Lowrie","year":"1992","unstructured":"Lowrie, E. & Lew, N. Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. Semin. Nephrol. 12, 276\u2013283 (1992).","journal-title":"Semin. Nephrol."},{"key":"72568_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ki.2011.179","volume":"80","author":"OF Bamgbola","year":"2011","unstructured":"Bamgbola, O. F. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int. 80, 464\u2013474 (2011).","journal-title":"Kidney Int."},{"key":"72568_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4236\/ojneph.2014.43018","volume":"4","author":"A Patel","year":"2014","unstructured":"Patel, A., Mehta, S., Waseef, A. & Saggi, S. Correction of severe anemia in a patient with end stage renal disease and myelodysplastic syndrome. Open J. Nephrol. 4, 125\u2013129 (2014).","journal-title":"Open J. Nephrol."},{"key":"72568_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5045\/br.2014.49.4.216","volume":"49","author":"V Visconte","year":"2014","unstructured":"Visconte, V., Tiu, R. V. & Rogers, H. J. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 49, 216\u2013227 (2014).","journal-title":"Blood Res."},{"issue":"7 Suppl","key":"72568_CR21","first-page":"S2","volume":"125","author":"MA Xiaomei","year":"2012","unstructured":"Xiaomei, M. A. Epidemiology of myelodysplastic syndromes . Am. J. Med. 125(7 Suppl), S2\u2013S5 (2012).","journal-title":"Am. J. Med."},{"key":"72568_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/10428199509059648","volume":"18","author":"F Morschhauser","year":"1995","unstructured":"Morschhauser, F. et al. glomerular injury in chronic myelomonocytic leukemia. Leuk Lymphoma. 18, 479\u2013483 (1995).","journal-title":"Leuk Lymphoma."},{"key":"72568_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2141.1995.tb05310.x","volume":"91","author":"H Enright","year":"1995","unstructured":"Enright, H. et al. paraneoplastic autoimmune phenomena in patients with myelodysplatic syndromes: response to immunosuppressive therapy. Br. J. Haematol. 91, 403\u2013408 (1995).","journal-title":"Br. J. Haematol."},{"key":"72568_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<200::AID-AJH6>3.0.CO;2-0","volume":"60","author":"T Saitoh","year":"1999","unstructured":"Saitoh, T. et al. Myelodysplatic syndromes with nephrotic syndrome. Am. J. Hematol. 60, 200\u2013204 (1999).","journal-title":"Am. J. Hematol."},{"key":"72568_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.krcp.2013.06.001","volume":"32","author":"KL Ko","year":"2013","unstructured":"Ko, K. L. et al. Membranous glomerulonephritis in a patient with myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia. Kidney Res. Clin. Pract. 32, 134\u2013137 (2013).","journal-title":"Kidney Res. Clin. Pract."},{"key":"72568_CR26","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/ndt\/17.7.1336","volume":"17","author":"T Apostolou","year":"2002","unstructured":"Apostolou, T. et al. Astheroembolic renal disease and membranous nephropathy, in a patient with myelodysplastic syndrome, eosinophilia, and trisomy 8. Nephrol. Dial. Transplant. 17, 1336\u20131338 (2002).","journal-title":"Nephrol. Dial. Transplant."},{"key":"72568_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s004670100025","volume":"16","author":"R Bogdanovic","year":"2001","unstructured":"Bogdanovic, R. et al. Glomerular involvement in myelodysplastic syndromes. Pediatr. Nephrol. 16, 1053\u20131057 (2001).","journal-title":"Pediatr. Nephrol."},{"key":"72568_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/ki.1994.117","volume":"45","author":"J Pereira","year":"1994","unstructured":"Pereira, J. et al. Plasma levels of IL-1\u00df, TNF-a and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialysis patients. Kidney Int. 45, 890\u2013896 (1994).","journal-title":"Kidney Int."},{"key":"72568_CR29","first-page":"428","volume":"4","author":"I MacDougall","year":"1993","unstructured":"MacDougall, I., Allen, D., Tucker, B., Baker, L. & Baker, A. Serum interleukin-6 levels are a useful indicator of marrow suppression in patients with resistance to erythropoietin due to inflammatory disease [abstract]. J. Am. Soc. Nephrol. 4, 428 (1993).","journal-title":"J. Am. Soc. Nephrol."},{"key":"72568_CR30","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/ndt\/gft267","volume":"29","author":"I Loeffler","year":"2014","unstructured":"Loeffler, I. & Wolf, G. Transforming growth factor-\u03b2 and the progression of renal disease. Nephrol. Dial. Transpl. 29, i37\u2013i45 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"72568_CR31","first-page":"22","volume":"98","author":"X Shi","year":"2019","unstructured":"Shi, X. et al. The inflammatory cytokine profile of myelodysplastic syndromes. Medicine. 98, 22 (2019).","journal-title":"Medicine."},{"key":"72568_CR32","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1182\/blood-2006-05-023093","volume":"108","author":"TA Navas","year":"2006","unstructured":"Navas, T. A. et al. Inhibition of overactivated p38MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 108, 4170\u20134177 (2006).","journal-title":"Blood"},{"key":"72568_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd1177","volume":"2","author":"S Kumar","year":"2003","unstructured":"Kumar, S., Boehm, J. & Lee, J. C. p38MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2, 717\u2013726 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"72568_CR34","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","volume":"101","author":"LC Platanias","year":"2003","unstructured":"Platanias, L. C. Map kinase signaling pathways and hematologic malignancies. Blood 101, 4667\u20134679 (2003).","journal-title":"Blood"},{"issue":"3","key":"72568_CR35","first-page":"e-213981","volume":"14","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. p38 MAPK activity is associated with the histological degree of interstitial fibrosis in IgA nephropathy patients. PLoS ONE 14(3), e-213981 (2019).","journal-title":"PLoS ONE"},{"key":"72568_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cbi.2015.08.026","volume":"240","author":"A Ahad","year":"2015","unstructured":"Ahad, A., Ahsan, H., Mujeeb, M. & Siddiqui, W. A. Gallic acid ameliorates renal functions by inhibiting the activation of p38MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells. Chem. Biol. Interact. 240, 292\u2013303 (2015).","journal-title":"Chem. Biol. Interact."},{"key":"72568_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-3-7643-8698-6_15","volume":"4","author":"TL Arvedson","year":"2009","unstructured":"Arvedson, T. L. & Sasu, B. J. Role and regulation of iron metabolism in erythropoiesis and disease. Erythrop. Erythrop. Fact. Erythrop. Milestones Drug Ther. 4, 279\u2013298 (2009).","journal-title":"Erythrop. Erythrop. Fact. Erythrop. Milestones Drug Ther."},{"issue":"Suppl 1","key":"72568_CR38","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/S0268-960X(09)70005-0","volume":"23","author":"P Fenaux","year":"2009","unstructured":"Fenaux, P. & Rose, C. Impact of iron overload in myelodysplastic syndromes. Blood Rev. 23(Suppl 1), S15-19 (2009).","journal-title":"Blood Rev."},{"key":"72568_CR39","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L Malcovati","year":"2005","unstructured":"Malcovati, L. et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23, 7594\u20137603 (2005).","journal-title":"J. Clin. Oncol."},{"key":"72568_CR40","doi-asserted-by":"publisher","first-page":"10181","DOI":"10.1038\/srep10181","volume":"5","author":"X Chai","year":"2015","unstructured":"Chai, X. et al. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem\/progenitor cells in mice. Sci. Rep. 5, 10181 (2015).","journal-title":"Sci. Rep."},{"key":"72568_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/ejh.12309","volume":"93","author":"H Okabe","year":"2014","unstructured":"Okabe, H. et al. The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice. Eur. J. Haematol. 93, 118\u2013128 (2014).","journal-title":"Eur. J. Haematol."},{"key":"72568_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12185-017-2367-1","volume":"107","author":"N Gattermann","year":"2018","unstructured":"Gattermann, N. Iron overload in myelodysplastic syndromes (MDS). Int. J. Hematol. 107, 55\u201363 (2018).","journal-title":"Int. J. Hematol."},{"key":"72568_CR43","first-page":"392","volume":"9","author":"L Lyle","year":"2018","unstructured":"Lyle, L. & Hirose, A. Iron overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment. J. Adv. Pract. Oncol. 9, 392\u2013405 (2018).","journal-title":"J. Adv. Pract. Oncol."},{"key":"72568_CR44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3324\/haematol.2012.077446","volume":"98","author":"I Ambaglio","year":"2013","unstructured":"Ambaglio, I. et al. Inappropriately low hepcidin levels in patients with myelodysplasitic syndrome carrying a somatic mutation of SF3B1. Haematologica 98, 420\u2013423 (2013).","journal-title":"Haematologica"},{"issue":"8","key":"72568_CR45","doi-asserted-by":"publisher","first-page":"e23109","DOI":"10.1371\/journal.pone.0023109","volume":"6","author":"V Santini","year":"2011","unstructured":"Santini, V. et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE 6(8), e23109 (2011).","journal-title":"PLoS ONE"},{"key":"72568_CR46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/ki.2009.357","volume":"76","author":"Y Cui","year":"2009","unstructured":"Cui, Y., Wu, Q. & Zhou, Y. Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int. 76, 1137\u20131141 (2009).","journal-title":"Kidney Int."},{"key":"72568_CR47","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1159\/000485865","volume":"42","author":"SW Lee","year":"2017","unstructured":"Lee, S. W. et al. Serum hepcidin and iron indices affect anemia status differently according to the kidney function of non-dialysis chronic kidney disease patients: Korean cohort study for outcome in patients with chronic kidney disease (KNOW-CKD). Kidney Blood Press. Res. 42, 1183\u20131192 (2017).","journal-title":"Kidney Blood Press. Res."},{"key":"72568_CR48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.15171\/jrip.2019.27","volume":"8","author":"F Ghahramanfard","year":"2019","unstructured":"Ghahramanfard, F. et al. Hepcidin in hemodialysis patients and its association with anemia and serum iron indices. J. Renal. Inj. Prev. 8, 146\u2013150 (2019).","journal-title":"J. Renal. Inj. Prev."},{"key":"72568_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","volume":"36","author":"T Ganz","year":"2016","unstructured":"Ganz, T. & Nemeth, E. Iron balance and the role of hepcidin in chronic kidney disease. Semin. Nephrol. 36, 87\u201393 (2016).","journal-title":"Semin. Nephrol."},{"key":"72568_CR50","first-page":"108","volume":"73","author":"NC van der Weerd","year":"2015","unstructured":"van der Weerd, N. C. et al. Hepcidin in chronic kidney disease: not an anemia management tool, but promising as a cardiovascular biomarker. Neth. J. Med. 73, 108\u2013118 (2015).","journal-title":"Neth. J. Med."},{"key":"72568_CR51","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1038\/s41598-017-04664-y","volume":"7","author":"SW Lee","year":"2017","unstructured":"Lee, S. W. et al. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Sci. Rep. 7, 4260 (2017).","journal-title":"Sci. Rep."},{"key":"72568_CR52","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo, R. A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45, 613\u2013619 (1992).","journal-title":"J. Clin. Epidemiol."},{"key":"72568_CR53","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","volume":"26","author":"JJ Dignam","year":"2008","unstructured":"Dignam, J. J. & Kocherginsky, M. N. Choice and interpretation of statistical tests used when competing risks are present. J. Clin. Oncol. 26, 4027\u20134034 (2008).","journal-title":"J. Clin. Oncol."},{"key":"72568_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2015.05.042","volume":"193","author":"PY Pai","year":"2015","unstructured":"Pai, P. Y. et al. Long term antihypertensive drug use and prostate cancer risk: a 9-year population-based cohort analysis. Int. J. Cardiol. 193, 1\u20137 (2015).","journal-title":"Int. J. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72568-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72568-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72568-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:09:40Z","timestamp":1670353780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72568-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72568"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72568-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"31 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15557"}}